| Literature DB >> 36042602 |
Hitomi Tanaka1, Takatoshi Anno1, Haruka Takenouchi1, Katsumasa Koyama1, Hideaki Kaneto2, Toru Oga3, Yasumasa Monobe4, Koichi Tomoda1.
Abstract
RATIONALE: Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a systemic immune-mediated condition that can cause fibroinflammatory lesions in multiple organs. Approximately 35% of IgG4-RD patients have some symptoms in the chest and IgG4-related lung disease (IgG4-RLD) is observed in about 10% of IgG4-RD cases. In addition, it is thought that glucocorticoid therapy is effective for IgG4-RD and IgG4-RLD. It is difficult to diagnose IgG4-RLD complicated with another lung disease. PATIENT CONCERNS: An 85-year-old Japanese man was hospitalized due to pulmonary consolidations just below the pleura in chest computed tomography while being treated with antibiotics. Previously, an upper lobectomy of the right lung was performed for an upper lung mucinous adenocarcinoma, and he was diagnosed with chronic obstructive pulmonary disease. Although he took antibiotics before admission, C-reactive protein levels were elevated. DIAGNOSIS: IgG4 levels were also elevated (IgG4; 733 mg/dL), and lung biopsy histology showed an abundance of IgG4-positive plasma cell infiltration; about 40% of the affected area was occupied by such infiltration. Based on such findings, we finally diagnosed him as IgG4-RLD.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36042602 PMCID: PMC9410645 DOI: 10.1097/MD.0000000000030285
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Laboratory data on admission in this subject.
| Variable | Result | Reference range | Variable | Result | Reference range |
|---|---|---|---|---|---|
|
|
| ||||
| White blood cells (/μL) | 7370 | 3300–8600 | PT-sec (s) | 13.3 | 9.3–12.5 |
| Neutrocyte (%) | 65.8 | 52.0–80.0 | PT-INR | 1.20 | 0.85–1.13 |
| Lymphocytes (%) | 22.8 | 20.0–40.0 | PT-activity (%) | 73.3 | 80.7–125.2 |
| Monocyte (%) | 7.9 | 1.0–6.0 | APTT (s) | 29.2 | 26.9–38.1 |
| Eosinocyte (%) | 2.8 | 1.0–5.0 | Fibrinogen (mg/dL) | 389 | 160–380 |
| Basocyte (%) | 0.7 | 0.0–1.0 |
| ||
| Red blood cells (×104/μL) | 382 | 435–555 | IgG (mg/dL) | 3119 | 861–1747 |
| Hemoglobin (g/dL) | 11.5 | 13.7–16.8 | IgA (mg/dL) | 320 | 93–393 |
| Platelets (×104/μL) | 23.3 | 15.8–34.8 | IgM (mg/dL) | 42 | 33–183 |
|
| IgG4 (mg/dL) | 733 | 11.0–121.0 | ||
| Total protein (g/dL) | 8.0 | 6.6–8.1 | SP-A (ng/mL) | 79.6 | <43.8 |
| Albumin (g/dL) | 3.2 | 4.1–5.1 | SP-D (ng/mL) | 216 | <110.0 |
| Globulin (g/dL) | 4.8 | 2.2–3.4 | KL-6 (U/mL) | 751 | <500 |
| Total bilirubin (mg/dL) | 0.5 | 0.4–1.5 |
| ||
| AST (U/L) | 25 | 13–30 | Anti-nuclear antibody | 9.9 (-) | <20.0 |
| ALT (U/L) | 10 | 10–42 | rheumatoid factor (U/L) | <15 | 0.0–15.0 |
| LDH (U/L) | 252 | 124–222 | Anti-ds-DNA Ab. (IU/mL) | <10 | 0–12 |
| ALP (U/L) | 304 | 106–322 | Anti-Sm Ab. (U/mL) | <1.0 | <10.0 |
| γ-GTP (U/L) | 25 | 13–64 | Anti-SS-A Ab. (U/mL) | <1.0 | <10.0 |
| BUN (mg/dL) | 52 | 8–20 | Anti-SS-B Ab. (U/mL) | <1.0 | <10.0 |
| Creatinine (mg/dL) | 1.65 | 0.65–1.07 | Anti-Scl-70 Ab. (U/mL) | <1.0 | <10.0 |
| Cholinesterase (U/L) | 215 | 240–486 | Anti-Jo-1 Ab. (U/mL) | <1.0 | <10.0 |
| Uric acid (mg/dL) | 9.3 | 3.7–7.8 | PR3-ANCA (U/mL) | <1.0 | <3.5 |
| CRP (mg/dL) | 1.85 | <0.14 | MPO-ANCA (U/mL) | <1.0 | <3.5 |
| Plasma glucose (mg/dL) | 127 | Anti-mitochondrial M2Ab. | <1.5 (-) | <7.0 | |
| Hemoglobin A1c (%) | 6.0 | 4.9–6.0 | Anti-ARS Ab. | 6.6 (-) | <25.0 |
| Total cholesterol (mg/dL) | 142 | 142–248 | Anti-MDA5 Ab. | <4 (-) | <32 |
| Sodium (mmol/L) | 138 | 138–145 | Anti-CCP Ab. (U/mL) | 1.1 | <4.5 |
| Potassium (mmol/L) | 4.1 | 3.6–4.8 | |||
| Chloride (mmol/L) | 107 | 101–108 | |||
ALP = alkaline phosphatase, ALT = alanine aminotransferase, Anti-aminoacyl tRNA synthetase antibody, Anti-CCP Ab. = Anti-cyclic citrullinated peptide antibody, Anti-ds-DNA Ab. = Anti-double stranded-deoxyribonucleic acid Antibody, Anti-Jo-1 Ab. = PR3-ANCA, proteinase 3 antineutrophil cytoplasmic antibodies, Anti-MDA5 Ab. = Anti-melanoma differentiation-associated gene 5 antibody, Anti-Mitochondrial M2 Ab. = Anti-ARS Ab., Anti-mitochondrial M2 antibody, Anti-Scl-70 Ab. = Anti-Scleroderma-70 antibody, Anti-Sm Ab. = Anti-Smith Antibody, Anti-SS-A Ab. = Anti-Sjögren-syndrome-related antigen A Antibody, Anti-SS-B Ab. = Anti-Sjögren-syndrome-related antigen B Antibody, APTT = activated partial thromboplastin time, AST = aspartate aminotransferase, BUN = blood urea nitrogen, CRP = C-reactive protein, Ig = immunoglobulin, KL-6 = krebs von den lungen-6, LDH = lactate dehydrogenase, MPO-ANCA = myeloperoxidase-antineutrophil cytoplasmic antibodies, PT = prothrombin time, PT-INR = PT-international normalized ratio, SP-A = pulmonary Surfactant Protein-A, SP-D = pulmonary Surfactant Protein-D, γ-GTP = γ-glutamyltranspeptidase.
Figure 1.Chest computed tomography (CT) 4 months before (upper panel), on admission (middle panel) and 4 weeks later (lower panel). Chest CT revealed the multifocal pulmonary consolidations just below the pleura (red arrow) on admission, although it was not detected about 4 months before. About 4 weeks after admission (about 2 weeks after injection of prednisolone), his multifocal pulmonary consolidations were improved.
Figure 2.(A and B) HE staining, (C) IgG staining, and (D) IgG4 staining of the lung tissue specimens. There was a marked infiltration of lymphocyte and plasma cells. Histological examination of lung biopsy showed the abundance in IgG4-positive plasma cell infiltration; about 40% of observation area was occupied by such infiltration. IgG4 = immunoglobulin G4.